$125 | Single User
$250 | Site License
$375 | Global License

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review [Report Updated: 06-09-2018]

Published by Global Data: 06 Sep 2018 | 221507 | In Stock

Introduction

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

e-Therapeutics Plc (e-Therapeutics) is a drug discovery and development company with focus on the treatment of cancer and neurodegeneration. It has a proprietary discovery platform based on network pharmacology and chemical biology for the discovery of drugs. The company focuses on immuno-oncology to tackle drug resistance in targeted cancer therapies and anti-infectives. It's under development drugs include ETS-2300, ETS-2400, ETS-3100, ETS-5200, ETS-6700. e-Therapeutics has development centers in Oxford and Newcastle. The company operates through one subsidiary, InRotis Technologies Limited. e-Therapeutics is headquartered in Long Hanborough, England, the UK.

e-Therapeutics Plc Key Recent Developments

Mar 27,2018: e-therapeutics: Full Year Results 2018

Nov 01,2017: e-Therapeutics: Appointment of Director

Sep 26,2017: e-Therapeutics: Interim Results for the 6 Months Ended 31 July 2017

Jul 27,2017: Edison issues update on e-Therapeutics (ETX)

Jul 24,2017: e-Therapeutics Announces Outcome of Strategic Review and Future Plans

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review [Report Updated: 06-09-2018]

  • Table of Contents

    Table of Contents 3

    List of Tables 4

    List of Figures 4

    Section 1 - About the Company 5

    e-Therapeutics Plc - Key Facts 5

    e-Therapeutics Plc - Key Employees 6

    e-Therapeutics Plc - Key Employee Biographies 7

    e-Therapeutics Plc - Major Products and Services 8

    e-Therapeutics Plc - History 9

    e-Therapeutics Plc - Company Statement 10

    e-Therapeutics Plc - Locations And Subsidiaries 11

    Head Office 11

    Other Locations & Subsidiaries 11

    Section 2 – Company Analysis 12

    Company Overview 12

    e-Therapeutics Plc - Business Description 13

    e-Therapeutics Plc - SWOT Analysis 14

    SWOT Analysis - Overview 14

    e-Therapeutics Plc - Strengths 14

    e-Therapeutics Plc - Weaknesses 15

    e-Therapeutics Plc - Opportunities 16

    e-Therapeutics Plc - Threats 17

    e-Therapeutics Plc - Key Competitors 18

    Section 3 – Company Financial Ratios 19

    Financial Ratios - Capital Market Ratios 19

    Financial Ratios - Annual Ratios 20

    Performance Chart 22

    Financial Performance 22

    Financial Ratios - Interim Ratios 23

    Financial Ratios - Ratio Charts 24

    Section 4 – Company’s Lifesciences Financial Deals and Alliances 25

    e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

    e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

    e-Therapeutics Plc, Recent Deals Summary 27

    Section 5 – Company’s Recent Developments 28

    Mar 27, 2018: e-therapeutics: Full Year Results 2018 28

    Nov 01, 2017: e-Therapeutics: Appointment of Director 33

    Sep 26, 2017: e-Therapeutics: Interim Results for the 6 Months Ended 31 July 2017 34

    Jul 27, 2017: Edison issues update on e-Therapeutics (ETX) 39

    Jul 24, 2017: e-Therapeutics Announces Outcome of Strategic Review and Future Plans 40

    Apr 19, 2017: e-Therapeutics: Full Year Results 43

    Apr 06, 2017: e-Therapeutics : Appointment of Chief Executive Officer 44

    Feb 16, 2017: e-Therapeutics Announces Directorate Change 45

    Jan 09, 2017: e-Therapeutics: Appointment of Amgen Executive Director as Chief Executive 46

    Section 6 – Appendix 47

    Methodology 47

    Ratio Definitions 47

    About GlobalData 51

    Contact Us 51

    Disclaimer 51

List Of Tables
in e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review [Report Updated: 06-09-2018]

List of Tables

e-Therapeutics Plc, Key Facts 5

e-Therapeutics Plc, Key Employees 6

e-Therapeutics Plc, Key Employee Biographies 7

e-Therapeutics Plc, Major Products and Services 8

e-Therapeutics Plc, History 9

e-Therapeutics Plc, Other Locations 11

e-Therapeutics Plc, Subsidiaries 11

e-Therapeutics Plc, Key Competitors 18

e-Therapeutics Plc, Ratios based on current share price 19

e-Therapeutics Plc, Annual Ratios 20

e-Therapeutics Plc, Annual Ratios (Cont...1) 21

e-Therapeutics Plc, Interim Ratios 23

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

e-Therapeutics Plc, Recent Deals Summary 27

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

List Of Figures, Charts and Diagrams
in e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review [Report Updated: 06-09-2018]

List of Figures

e-Therapeutics Plc, Performance Chart (2014 - 2018) 22

e-Therapeutics Plc, Ratio Charts 24

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 26

Additional Details

Publisher

Global Data

Publisher Information

Reference

221507 | GDPH82612FSA

Number of Pages

51

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Acorda Therapeutics Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Anika Therapeutics Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Nektar Therapeutics Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
United Therapeutics Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens ...
07 Jun 2016 by La Merie USD $2,750 More Info
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016 This Competitive Intelli...
01 Jun 2016 by La Merie USD $225 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Allied Healthcare Products, Inc. (AHPI) - Financial and Strategic SWOT Analysis Review
Allied Healthcare Products, Inc. (AHPI) - Financial and Strategic SWOT Analysis Review provides you ...
20 Oct 2015 by Global Data USD $125 More Info
SDI Limited (SDI) - Financial and Strategic SWOT Analysis Review
SDI Limited (SDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic ...
20 Oct 2015 by Global Data USD $125 More Info

This report is published by Global Data

Download Free Report Summary PDF

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review [Report Updated: 06-09-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data